Please login to the form below

Not currently logged in
Email:
Password:

Fraxiparine

This page shows the latest Fraxiparine news and features for those working in and with pharma, biotech and healthcare.

GSK sells another chunk of South Africa's Aspen

GSK sells another chunk of South Africa's Aspen

GSK has a longstanding relationship with Aspen, which included the sales of its thrombosis treatments products Arixtra (fondaparinux sodium) and Fraxiparine (nadroparin) to the South African firm in 2012 in a

Latest news

  • GSK plans to sell off older products GSK plans to sell off older products

    It has already started disposing of some other assets, for example selling anticoagulants Arixtra (fondaparinux sodium) and Fraxiparine (nadroparin) to South Africa's Aspen in a £700m deal last year.

  • GSK cashes in its stake in Africa's Aspen GSK cashes in its stake in Africa's Aspen

    Last year, Aspen took control of a GSK generic drugs unit in Australia, while in October it bought a GSK plant in France and thrombosis treatments Arixtra (fondaparinux sodium) and Fraxiparine

  • GSK sells off anticoagulants for £700m GSK sells off anticoagulants for £700m

    Fraxiparine is also used to treat blood clots, and has consistently achieved revenues of more than £200m for the last few years. ... potential. He said: “Arixtra and Fraxiparine are established products that have consistently delivered strong revenues.

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mind+Matter

We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...

Latest intelligence

How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....